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2Abstract
Objective: Malignant pleural mesothelioma (MPM) is a rare malignancy associated with 
exposure to asbestos. The protracted latent period of MPM means that its incidence has 
continued to rise across Europe after the introduction of restrictions on asbestos use. In 
order to obtain a clearer indication of trends in the Republic of Ireland (ROI), incidence and 
survival were assessed based on all MPM cases reported since the establishment of the 
National Cancer Registry of Ireland (NCR). 
Methods NCR recorded 337 MPM diagnoses in the ROI during 1994-2009. Survival was 
assessed for all cases diagnosed with adequate follow-up (n=330). Crude and European 
age-standardized incidence rates were calculated for all cases and for 4-year periods. A Cox 
model of observed (all-cause) survival was used to generate hazard ratios for the effect of: 
gender; age at diagnosis; diagnosis cohort; region of residence; histological type; and 
tumour stage. Single p-values for the variables indicated were calculated using either a 
stratified log-rank test or stratified trend test. 
Results: Over the study period the age-standardized MPM incidence in the ROI rose from 
4.98 cases per million (cpm) to 7.24 cpm. The 1-yr survival rate for all MPM cases was 
29.6% (CI 24.7-34.6%). Excess mortality risk was associated with age at diagnosis (75-89 
yrs vs. 55-64 yrs, HR 1.88, 95% CI 1.35-2.63, P<0.001) and tumour stage (III vs. I HR 1.57, 
95% CI 1.00-2.48, P<0.05; IV vs. I HR 1.55, 95% CI 1.08-2.21, P<0.05). Age showed a 
significant survival trend (P<0.001) but tumour stage did not (P=0.150). There was 
significant heterogeneity between the survival of patients resident in different regions 
(P=0.027).
Conclusion: MPM incidence and mortality continued to rise in the ROI after the restrictions 
on asbestos use and the predictors of survival detected in this study are broadly consistent 
with those identified for other countries. 
31. Introduction
Exposure to the asbestos group of silicate minerals is the greatest risk factor for the 
development of malignant pleural mesothelioma (MPM) (1). The six minerals categorised as 
‘asbestos’ are divided into two structural types: amphibole and serpentine, with amphibole 
minerals having the greatest carcinogenicity. Legislation enacted since the mid 1980s has 
progressively limited the use of asbestos in the Republic of Ireland (ROI), and the 
importation and use of all asbestos was banned in 2000 following the introduction of 
legislation by the European Union. Despite the widespread use of asbestos over past 
decades and its continued presence in existing buildings, few studies have been carried out 
on MPM incidence or survival in the ROI. 
Most cases of MPM diagnosed in the ROI between 1994 and 1998 were in individuals 
involved in construction-related trades (2). That study showed an annual increase of 14.4% 
in MPM incidence (P=0.08) and predicted a large increase in incidence over coming 
decades. A geographical comparison study on the incidence of MPM and other 
mesotheliomas in patients diagnosed between 1978 and 2002, across five European 
regions, grouped the UK and ROI together as one region (3). That study concluded that the 
European age-standardized incidence of pleural and pericardial mesothelioma was highest 
in the UK and ROI, at 18.2 cases per million (cpm) per year,  compared with 10 in Northern 
Europe, 12.1 in Central Europe, 3.3 in Eastern Europe and 11.4 in Southern Europe. 
Patients diagnosed with MPM in the UK and ROI also had a lower 1-yr survival (31%) 
compared with patients in other regions (34%-48%) (3). Gender differences in MPM survival 
have been observed in multiple studies from various parts of the World. (4) (5). The gender 
dichotomy has variously been attributed to the greater burden of asbestos fibres in the lungs 
of male patients compared to females (5) or the tumour suppressive actions of oestrogen 
receptor beta activation by circulating oestrogens, so attenuating tumour cell growth and 
MPM progression (6, 7).  
4We performed analysis on all MPM cases diagnosed in the ROI between 1994 and 2009, to 
provide more comprehensive figures on MPM incidence here and to assess factors 
influencing survival.  
2. Methods 
The data source for this study was the National Cancer Registry, Ireland (NCR). The NCR 
was established in 1991 and has recorded all cancer diagnoses made in the ROI for the 
years 1994 onwards. The data collated by the NCR have been used in many epidemiological 
studies and include age at diagnosis, gender, post-diagnosis survival, histological type, 
tumour stage, occupation and geographical region of residence. Data were analysed for all 
cases of MPM recorded by the NCR between 1994 and 2009. The age-standardized 
incidence rates were calculated for the time periods shown and for the whole study period 
using the European standard population distribution (8). Observed (all-cause) and relative 
survival estimates to five years after diagnosis were calculated actuarially using STATA-11 
software (StataCorp LP, Texas). Follow-up intervals used were three months in the first year 
after diagnosis, six months in the second and third years, and annually thereafter. Follow-up 
was based on linkage of cases to national death certificate data held by the Central Statistics 
Office, Ireland, covering deaths up to the end of 2010, supplemented by clinical information 
for some patients. Deaths after 31st December 2010 were excluded. 
A total of 337 MPM cases were diagnosed over the study period (1994-2009) (Table 1). Of 
16 patients without a recorded death up to the end of 2010, 6 were known to have died after 
2010 and, along with 3 patients diagnosed in 2008 or 2009, were assumed to be still alive at 
the end of 2010. For the seven remaining patients (diagnosed 1995-2003) without recorded 
death data, follow-up was censored on the most recently available treatment or hospital in-
patient date.  Adequate follow-up (1 day) was available for 330 patients (Table 1). A Cox 
model of observed (all-cause) survival, adjusted for age, gender, region and stage, and 
stratified for histological subtype (epithelioid, sarcomatoid, biphasic and undetermined) and 
5diagnosis period to allow for non-proportional hazards shown by these variables, was used 
to generate hazard ratios for the effect of patient and tumour factors (Table 1). For 
comparison, a less optimal model was also applied, adjusted but not stratified for subtype 
and region. Equivalent models of relative survival were also applied, giving very similar 
results (not reported here). The heterogeneity of each  survival by gender, diagnosis cohort, 
HSE region and histological sub-type was assessed using a stratified log-rank test for 
equality of survivor function. Trends in survival by age and tumour stage (I-IV) at diagnosis 
were assessed by stratified trend tests. Cause-specific survival was not assessed in this 
study because of the high proportion of unknown or undisclosed causes of death for this 
patient group. Restriction of statistical analysis to 1-yr or 3-yr follow-up did not appreciably 
change the findings compared to models based on 5-yr follow-up presented here. 
3. Results 
Incidence
There were 337 MPM diagnoses in the ROI over the period 1994-2009. Survival data were 
available for 330 patients - 289 male (87.6%) and 41 female (12.4%) (Table 1). There was 
an upward trend in the number of MPM diagnoses made over the study period, from 58 
MPM diagnoses during the four-year period 1994-1997 to 114 during 2006-2009 (Table 1). 
This represents a mean rise in annual incidence from 4.98 cases per million (cpm) 1994-
1997 to 7.24 cpm 2006-2009. Of those cases with adequate post diagnosis follow-up for 
survival analysis, only a small number of cases 43 (13%) were diagnosed in individuals <55 
years of age; this is consistent with the model of MPM disease progression where 
malignancy develops often decades after exposure to the carcinogen. Incidence rates were 
also calculated for all primary pleural malignancies diagnosed over the study period (n=438), 
sub-categorised into MPM and non-MPM (NM), and the age-standardized incidence was 
compared for each of the four-year periods (Table 3). NM incidence among females was 
0.56 cpm and 0.64 cpm for periods 1994-1997 and 2006-2009 respectively, while in males 
6the rate declined from 3.45 cpm to 2.11 cpm. Over the same period the incidence of MPM 
among males rose from 9.08 cpm to 13.11 cpm. 
Gender
The observed one-yr post-diagnosis survival for male patients was 28.6% (95% CI 23.5-
33.9%), and 36.6% (95% CI 22.2–50.9%) for females (Table 2, Fig. 1A). Median survival 
was 197 days in males, 253 days in females. Survival was significantly better among female 
patients in an adjusted but un-stratified model of observed survival with a hazard ratio (HR) 
0.68 (95% CI 0.47-0.98, P=0.036) compared to males, but was not significant in a fully 
stratified model (Table 1 and footnote). 
Age at Diagnosis 
At diagnosis, 43 (13%) of the patients in this cohort were aged 18-54 years, 113 (34.2%) 55-
64 years, 107 (32.4%) 65-74 years and 67 (20.3%) were aged 75-89 years (Table 2). In total 
287 (87%) of the patients were aged over 55 years at the time of MPM diagnosis. Compared 
with age-group 55-64, observed survival was significantly poorer in age-group 75-89 (HR 
1.88, 1.35–2.63, P<0.001) (Table 1, Fig. 1B). There was a significant overall trend in survival 
by age (P<0.001). The proportion of patients diagnosed below age 55 fell from 22% (13 
cases) during 1994-1997 to 7% (8) during 2006-2009, while diagnoses at 75 years or over 
rose from 17% (10) to 28% (33) over the same timescale. 
Diagnosis Cohort 
The cases included for survival analysis spanned a 16-year diagnosis period (Table 2), and 
possible variation in survival over time was examined and adjusted for using four-year 
cohorts (Fig. 1D). The 1-yr survival rate for the whole study population was 29.6% (95% CI 
24.7-34.6%). The 1-yr survival rate for each of the study cohorts was: 1994-1997, 27.0% 
(95% CI 16.1-38.9%); 1998-2001, 20.6% (CI 11.7-31.3%); 2002-2005, 36.8% (27.2-46.4%); 
and 2006-2009, 29.8% (CI 21.7-38.3%). Definitive hazard ratios for cohort could not be 
7computed, because of non-proportional hazards. An unstratified model indicated significantly 
poorer survival for the 1998-2001 cohort (Table 1 and footnote), but a stratified log-rank test 
did not identify significant heterogeneity between the diagnosis cohorts (P= 0.184). 
Histological Subtype 
Malignant mesothelioma can be classified by the histological morphology of tumour cells 
during haematoxylin-eosin staining as epithelioid, sarcomatoid or mixed (biphasic). 
Epithelioid MPM is characterized by polygonal, oval, or cuboidal cells that often mimic non-
neoplastic reactive mesothelial cells. Sarcomatoid MPM tumours consist of spindle-shaped 
cells, and biphasic MPM contains both epithelioid areas and sarcomatoid areas within the 
same tumour (9). The histological subtype was available for only 81 (24.5%) of the 330 Irish 
MPM cases included in the survival analysis, of which 63 (77.8%) were diagnosed as 
epithelioid, 14 (17.3%) biphasic and 4 (4.9%) as sarcomatoid (Table 1), which is consistent 
with previous studies showing epithelioid is the most common histological subtype followed 
by biphasic and sarcomatoid MPM (10, 11). The final Cox model was stratified for subtype 
because of non-proportional hazards, but an equivalent but unstratified model failed to 
confirm any statistically significant survival variation by subtype.  
Tumour Stage at Diagnosis  
TNM staging information was available for only 153 (46.4%) of the MPM cases in the 
survival cohort (Table 1, Fig. 1F), on the assumption that the N category was N0 and M 
category was M0 unless there was an explicit statement of node-positive or distant 
metastatic disease. Most cases were either un-staged (lacking a T-category) or were 
assigned to stage I, III or IV, with few assigned to stage II (possibly an artefact of the TNM 
staging criteria and data incompleteness). In the Cox model examined, survival of stage III 
and IV patients was significantly poorer, compared with stage I (Table 1): HR for stage III 
1.58 (95% CI 1.00-2.48, P<0.05), HR for stage IV 1.67 (95% CI 1.09-2.55, P<0.05).  
8Region of Residence 
The provision of public hospital healthcare in the ROI is administered through four HSE 
administrative areas (Table 1). HSE region of residence is associated with survival for some 
other cancers in Ireland, and was thus included in analyses here. There was some 
suggestion of higher survival for Dublin / North-East region, and lower survival for the 
Western region, compared with Dublin / Mid-Leinster (Table 1), but neither was statistical 
significantly. However, a stratified log-rank test indicated significant heterogeneity between 
the regions (P=0.027).
Therapeutic Intervention 
In the Irish cohort 140 patients (44% of the total) did not receive radiotherapy, chemotherapy 
or surgical intervention, and the median survival for these patients was only 2.8 months, 
compared with 9.0 months for patients who did receive some kind of therapeutic intervention 
(not tabulated). The decision on whether chemotherapy is administered is based on multiple 
factors including predicted response and current health status, and it is probable that those 
who received chemotherapeutic intervention had other positive indicators which also 
contributed to their improved survival. Of patients diagnosed during 1994-1997, 21 (36%) 
received some form of tumour-directed therapy; this increased to 91 patients (69%) for 2006-
2009. Survival seemed to be poorest in the 1998-2001 diagnosis group, where multimodal 
therapy was used at lowest frequency to treat only 5 patients (8%).  For those patients 
where tumour stage was known (n=153), 14 (30%) of stage III patients did not receive 
treatment compared to 23 (41%) of stage IV patients.
Occupation 
The last occupation of 223 of 362 MPM patients diagnosed between 1994 and 2010 was 
known. The occupations most highly represented were: construction (28 cases); 
woodworking (22 cases); managers working in agriculture or forestry (18 cases); plant and 
9machine operators (13 cases); road transport workers (13 cases) and mining/ manufacturing 
workers (13 cases). 
4. Discussion 
The average incidence of MPM in the Republic of Ireland over the period 1994-2009 
(European population age-standardized rate [EASR] 6.02 cases per million and crude rate 
5.34 cpm) is comparable with the crude rates of MPM observed in some European countries 
such as Austria (5.6  cpm), Poland (4 cpm) and Spain (4 cpm), but lower than reported in 
others such as Norway (16 cpm), Sweden (12 cpm), France (10-13 cpm), over a similar 
period (12). That review also quoted a crude rate of 30 cpm for Great Britain, derived from 
mortality data. European data from the RARECARE project for 1995-2002 indicated a higher 
EASR of pleural or pericardial mesothelioma for the UK and ROI combined (18.2 cpm) than 
for four other regions of Europe (range 3.3-12.1 cpm) (3). More recent figures indicate an 
EASR for all mesothelioma averaging 31 cpm for the whole of the UK and 17 cpm for 
Northern Ireland in 2009 (http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/Mesothelioma/incidence/#In), compared with a total mesothelioma 
EASR for the ROI of 7.24 cpm during 2006-2009 (6.02 1994-2009).  
Differences in the scale of asbestos use possibly contribute to the apparent differences in 
MPM incidence between the UK and ROI. The peak in asbestos importation here occurred in 
1980 at 8,413 tonnes compared to the 1975 peak for the UK at 139,185 tonnes (13), and 
overall asbestos use in the ROI has been much less intensive than in the UK.  However, the 
implementation of the ban occurred later, and in 1996 asbestos importation into the ROI was 
4,638 tonnes (67.7% of peak) compared to 7,099 tonnes (5.1% of peak) in the UK. Most 
cases of MPM arising today in the UK are assumed to be the result of exposure to fire 
retardant amosite (brown asbestos) that was incorporated into building materials (14). The 
contribution of serpentine white asbestos (chrysotile) to malignancy remains controversial, 
and most malignancies arising from chrysotile exposure are believed to be the result of 
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natural contamination with amphibole asbestos sub-types, or the mixing of chrysotile with 
amphiboles in the manufacture of some building materials (15). Precise data on the 
quantities of individual asbestos subtypes imported into the ROI are not available. MPM is a 
disease of extremely long latency where 40 years may lapse between exposure to asbestos 
and the diagnosis of malignancy. Since low-level but sustained importation of asbestos 
containing materials continued into the 1990s, it is not surprising that there has been a 
progressive increase in age-adjusted incidence of MPM in each of the study cohorts from 
1994 to 2009. This increase is consistent with data from other European countries where 
MPM incidence has continued to rise even after the asbestos ban. We noted that the 
percentage of cases diagnosed in patients over the age of 75 years in ROI over the study 
period rose from 17% to 28%, while the number diagnoses under the age of 55 years 
declined. The shift in the MPM burden to a more elderly demographic group has implications 
for future healthcare planning. It is likely that the incidence in Ireland will peak over the next 
decade, with the increasing age of diagnosis for the most highly exposed sub-set of the 
population
To investigate whether diagnostic improvements in distinguishing MPM from other (or 
unspecified) pleural malignancies could account for the apparent change in incidence over 
the study period, the incidence for MPM and non-mesothelioma or unspecified pleural 
neoplasms (NM) were compared. The latter can arise from metastatic invasion of the pleura 
by other malignancies such as lung or breast carcinoma (16, 17), but cases registered by the 
NCR should be primary pleural neoplasms only and may include some unconfirmed 
mesothelioma. Cases registered as mesothelioma under current NCR rules must be 
microscopically verified (except for death-certificate-only cases), and purely clinical or 
radiological diagnoses of mesothelioma are coded as ‘unknown cancer morphology.’ Total 
numbers of NM cases declined from 21 during 1994-1997 to 17 during 2009-2009, and rates 
of NM showed no clear trend, in contrast to the marked rise in MPM diagnoses. The 
incidence of all pleural malignancies rose from 6.98 to 7.77 cpm over the study period, most 
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of this increase attributable to the increase in MPM incidence. However, the more marked 
increase in MPM incidence over time, compared with all pleural malignancies, suggests that 
some of the MPM trend may be accounted for by improved specificity of diagnoses.  
A number of factors may contribute to survival differences between diagnosis periods or 
patient groups. Survival appeared to be poorest in the second-earliest diagnosis cohort, and 
to improve more recently, although a log-rank test (stratified for other factors) did not confirm 
significant heterogeneity (P=0.184), and chance effects could not be rule out. Lead time-bias 
is significant consideration in interpreting survival data, and may have contributed to some of 
the survival differences between subgroups in this study. Different patient cohorts may be 
separated by a significant period of time when diagnostic practices may have changed, and 
age group or gender may influence an individual’s motivation for seeking timely medical 
advice (18). In 1996 a National Cancer Strategy to improve infrastructure and service 
provision was implemented in ROI (19). This provided a national framework for the 
development and funding of cancer care after inconsistencies in treatment were found at 
different centres and may have contributed to improvements in care in recent years. 
Nevertheless, we found significant heterogeneity in survival by region of residence.
Therapeutic practices in ROI have changed over the study period with the percentage of 
patients receiving some intervention rising from 36% to 69%. The more extensive use of 
single mode and multimodal interventions (most often chemotherapy in combination with 
surgery or radiotherapy) after 2002 may contribute to apparent survival differences over the 
different diagnosis periods. Progressively these limited therapeutic improvements may come 
to be confounded by the increasing age of patients at diagnosis, which affects their suitability 
for particular interventions and so may restrict future use of some therapies, particularly 
surgery.
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The histological subtype is one of the most important prognostic indicators influencing MPM 
survival. Patients diagnosed with epithelioid MPM have longer post-diagnosis survival times, 
patients with sarcomatoid MPM shorter survival and patients with biphasic MPM, 
intermediate survival (20). Histological subtype influences the selection of specific 
therapeutic regimes, with sarcomatoid patients not being appropriate for surgery. Data 
presented in this study refers to the histological sub-type at diagnosis, but sub-type plasticity 
and progression to a sarcomatoid tumour cell phenotype over time would adversely affect 
survival. Such an epithelial-mesenchymal transition in MPM has been linked to a loss of 
PTEN activity in tumour cells (21). Higher Butchart (22) or TNM (23) tumour stage 
classification at diagnosis for MPM correlates with worse survival. Data from this present 
study is based on tumour stage at diagnosis and indicates that patients diagnosed at tumour 
stages III and IV have a worse survival than those who are diagnosed at stage I. However, 
no further conclusion could be drawn on the contribution of histological type or tumour stage 
in this cohort of patients due to the limited tumour classification data available. We also have 
no information on tumour stage progression, or on possible changes over time in the 
thoroughness of stage investigations (which might lead to ‘stage migration’).  
The male/female ratio of patients diagnosed with MPM in Ireland during 1994-2009 was 7.0 
which is somewhat higher than that reported in England (1997-2007) at 5.7 (24) and 
Australia at 5.4 (25), but much higher than that reported for some other countries such as 
France at 3.8 (26) and Italy at 2.4 (25). Differences in occupational versus environmental 
asbestos exposure might possibly explain differences in the male/female incidence ratio 
between countries. The (probably) over-represented occupations of patients diagnosed with 
MPM in the ROI (Table 4) include construction trades, metal working, electrical trades and 
mining which are associated with greater asbestos exposure and which have a largely male 
workforce (27, 28). However, without the availability of complete information on occupation 
(and occupational exposures over time), including comparative information for other cancers, 
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caution is required in drawing any conclusions from the limited occupational data presented 
here.
The median survival for MPM patients in the ROI was 6.5 months for males and 8.3 months 
for females. This is comparable with MPM survival reported for England at 8.9 months (29), 
the US at 7 months (30) and Japan at 5-6 months (31). A significantly improved survival for 
female patients has been described in other studies and has been attributed to reduced 
asbestos fibre load (5) or the tumour suppressive action of circulating oestrogens (6, 7). 
Female gender was a positive predictor of survival in this study in a non-stratified Cox 
model. It has been proposed that circulating oestrogens attenuate the progression from 
epithelioid to sarcomatoid MPM in females (7), thus gender and histological subtype may not 
be independent variables. However, the lack of fuller (including post-diagnosis) information 
on histological subtype for this cohort prevents further investigation.  
Even though the majority of MPM cases occur later in life, it is clear that there is a 
percentage of MPM cases that are diagnosed in younger patients (27, 31). It is possible that 
such cases occur due to asbestos exposure in the urban environment rather than 
occupational exposure; however a genetic predisposition to developing MPM may also 
account for younger cases (32).  
5. Conclusion 
MPM is a rare malignancy, but the number of MPM diagnoses made in the Republic of 
Ireland has continued to rise over the period 1994-2009, consistent with observations made 
in other industrialised countries. The impact of survival predictors such as gender, 
histological type, tumour stage and age at diagnosis measured in this group of subjects is 
comparable with data from other studies. 
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Figure Legends
Figure 1.
Observed survival of pleural mesothelioma cases recorded in the Republic of Ireland 
between 1994 and 2009 with follow-up to December 31st 2010 (N=330). Individual survival 
curves are plotted by gender (A); age at diagnosis (B); age at diagnosis above or below 55 
years for each gender (C); diagnosis cohort (D);  histological subtype (E); tumour grade (F); 
and region of diagnosis (G). 
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Figure 1 
Table 1. Case numbers, and influence of gender and other factors on observed survival of 
pleural mesothelioma patients diagnosed 1994-2009 (based on follow-up to 31/12/2010. 
n (%) HRb 95% CI Pc age-adjusted  
(& crude) rate 
 per milliona
n (for survival 
analysis) 
Diagnosis cohort   P=0.184
1994-1997 59 (16.3) - -  4.98 (4.08) 58 
1998-2001 64 (17.7) - -  5.04 (4.24) 63 
2002-2005 97 (26.8) - -  6.85 (6.03) 95 
2006-2009 117 (32.3) - -  7.24 (6.70) 114 
       
1994-2009 337 (100) - -  6.02 (5.34) 330 
       
HSE region of residence    P=0.027    
Dublin/Mid-Leinster 105 (31.8) 1.00 -     
Dublin/North-East 60 (18.2) 0.77 0.54-1.10
South 87 (26.4) 0.98 0.70-1.35
West 78 (23.6) 1.24 0.90-1.72
      
Age (years) at diagnosis  P<0.001    
18-54 43 (13.0) 0.78 0.53-1.16     
55-64 113 (34.2) 1.00 - 
65-74 107 (32.4) 1.18 0.87-1.58
75-89 67 (20.3) ***1.88 1.35-2.63
      
Gender P=0.778    
Male 289 (87.6) 1.00 -     
Female 41 (12.4) 0.80 0.55-1.16
       
Histology type n (% of 81 
known) 
 P=0.762    
Epithelioid 63 (77.8) - -     
Biphasic 14 (17.3) - -     
Sarcomatoid 4 (4.9) - -     
Unspecified 249 - -     
     
Tumour stage n (% of 153 
known) 
 P=0.150    
I 48 (31.4) 1.00 -     
II 3 (2.0) 1.26 0.37-4.22 
III 46 (30.0) *1.58 1.00-2.48 
IV 56 (36.6) *1.67 1.09-2.55 
Unknown 177 1.08 - 
aAge-standardized rates per million per year using the European standard population (crude rates in 
parentheses)). Age-standardized rate is calculated as the mean (or midpoint) of the age-standardized rates for 
males and females separately, crude rate as sum of male and female cases/sum of male and female populations. 
The age-standardized (and crude) rates for mesothelioma of all sites combined  (not just pleura) were 5.39 (4.49) 
cpm for 1994-1997, 5.14 (4.51) 1998-2001, 7.78 (7.15) 2002-2005, 7.83 (7.22) 2006-2009 and 6.62 (5.93) 
1994-2009. 
bCox model of observed survival, stratified by subtype and diagnosis cohort to allow for non-proportional 
hazards, also adjusted for gender, age, region, and stage. In an equivalent but less optimal model, adjusted for 
but not stratified by subtype and diagnosis cohort, the HR for female gender was 0.68 (95% CI 0.47-0.98, 
P=0.036); HRs for subtype, relative to unspecified subtype, were 0.59 (0.20-1.72, P=0.332) for epithelioid, 0.79 
(0.58-1.06, P=0.118) for sarcomatoid and 1.31 (0.75-2.28, P=0.347) for biphasic; HR for 1998-2001 relative to 
1994-1997 cohort was 1.73 (1.18-2.55, P=0.005), otherwise no significant variation by cohort; HRs for age and 
stage showed little change. 
cP-value from log-rank test for equality of survivor functions or (for age and stages I-IV) from trend test, all 
adjusted for (stratified by) the other variables listed. 
*P<0.05, ** P<0.01, *** P<0.001. 
Table 2. Observed (all-cause) survival of pleural mesothelioma patients diagnosed in 
Ireland, 1994-2009 (based on follow-up to 31/12/2010). 
  1-yr   3-yr   5-yr  
 n survival 95% CI  survival 95% CI  survival 95% CI 
   
1994-2009 330 29.6% 24.7-34.6%  4.3% 2.3-7.1%  1.6% 0.5-3.7% 
   
males 289 28.6% 23.5-33.9%  4.2% 2.2-7.3%  0.9% 0.2-3.1% 
females 41 36.6% 22.2-50.9%  4.9% 0.9-14.5%  4.9% 0.9-14.5% 
   
age 18-54 43 45.4% 30.0-59.5%  6.8% 1.4-18.5%  3.4% 0.3-14.3% 
55-64 113 32.7% 24.3-41.4%  5.4% 2.1-11.1%  2.2% 0.4-6.8% 
65-74 107 29.3% 20.9-38.1%  2.5% 0.5-7.5%  1.3% 0.1-5.9% 
75-89 67 14.9% 7.7-24.4%  3.5% 0.7-10.5% -
55-89 287 27.3% 22.2-32.5%  3.9% 2.0-6.9%  1.3% 0.4-3.5% 
   
epithelioid 63 39.7% 27.6-51.4%  1.8% 0.2-8.3% 
sarcomatoid 4 - - -
biphasic 14 14.3% 2.3-36.5% 
unspecified  249 28.0% 22.5-33.6%  4.9% 2.5-8.4%  1.6% 0.5-4.3% 
   
Dublin / Mid-Leinster 105 30.5% 21.9-39.3%  2.6% 0.5-7.9%  1.3% 0.1-6.1% 
Dublin / North-East 60 35.0% 23.2-46.9%  8.3% 2.9-17.5%  2.1% 0.2-9.4% 
South 87 28.4% 19.2-38.1%  4.6% 1.3-11.3% -
West 78 25.6% 16.5-35.6%  2.9% 0.6-8.8%  2.9% 0.6-8.8% 
   
Stage I 48 37.5% 24.0-50.8%  4.8% 0.9-14.1% -
Stage II 3 - - -
Stage III 46 19.6% 9.7-32.0%  6.5% 1.7-16.0%  4.4% 0.8-13.0% 
Stage IV 56 22.0% 12.1-33.6% 0.0% -
Stage unknown 177 31.9% 25.1-38.7%  4.8% 2.1-9.3%  1.6% 0.3-5.1% 
   
1994-1997 58 27.0% 16.1-38.9%  9.8% 3.7-19.5%  3.9% 0.7-11.8% 
1998-2001 63 20.6% 11.7-31.3%  1.6% 0.1-7.5%  1.6% 0.1-7.5% 
2002-2005 95 36.8% 27.2-46.4%  4.4% 1.5-10.0%  1.1% 0.1-5.4% 
2006-2009 114 29.8% 21.7-38.3%  2.2% 0.3-8.8% -
   
Table 3. All cases of pleural malignancy (excluding lymphoma) diagnosed in the Republic of 
Ireland 1994-2009 to December 31st 2009 (n=438) divided into malignant pleural 
mesothelioma (MPM) and non-mesothelioma (NM). The incidence and age-adjusted rate are 
categorised by gender and diagnosis cohort. 
Cohort Gender n Age-adjusted rate per million a
 MPM NM All  MPM NM All 
1994-1997 M 54 21 75 9.08 3.45 12.53 
 F  5 4 9  0.89 0.56 1.44 
 total  59 25 84  4.98 2.00 6.98 
     
1998-2001 M  51 20 71  8.02 3.16 11.19 
 F  13 9 22  2.05 0.95 3.0 
 total  64 29 93  5.04 2.05 7.09 
     
2002-2005 M  87 15 102  12.35 2.33 14.67 
 F  10 7 17  1.33 0.83 2.16 
 total  97 22 119  6.85 3.16 8.41 
     
2006-2009 M  104 17 121  13.11 2.11 15.23 
 F  13 8 21  1.36 0.64 2.00 
 total  117 25 142  7.24 1.37 8.61 
          
          
1994-2009 M  296 73 369  10.64 2.76 13.40 
 F  41 28 69  1.41 0.74 2.15 
 total  337 101 438  6.02 1.75 7.77 
          
a European population age-standardized rates.  
Table 4. Occupational distribution of pleural mesothelioma cases diagnosed in the 
Republic of Ireland 1994-2010. 
Occupation Number of Diagnoses 
Construction Trades  28 
Woodworking Trades  22 
Managers in Farming, Horticulture, Forestry and Fishing 18 
Plant and Machine Operatives NEC 13 
Road Transport Operatives  13 
Other Occupations in Mining and Manufacturing  13 
Metal Forming, Welding and Related Trades  11 
Electrical/Electronic Trades 10 
Managers and Proprietors in Service Industries  7 
Sales Assistants and Check-Out Operators  5 
Not Classified 6 
Occupation groups with <5 members 77 
Unknown 139 
N=362
